How the latest AI innovations are reshaping diagnostics, patient access, international care journeys, and the future of health-service value.
| Editorial angle: AI’s real health-sector value is not automation for its own sake. It is the capacity to reduce friction across the patient journey: earlier diagnosis, lower administrative burden, better navigation, multilingual access, remote follow-up, and safer cross-border care. |
From Digital Promise to Clinical Infrastructure
Artificial intelligence is no longer a futuristic add-on to healthcare. It is becoming part of the operating system of modern medicine: helping clinicians interpret images, supporting earlier diagnosis, improving hospital workflows, accelerating drug development, and guiding patients through complex care journeys.
The U.S. Food and Drug Administration now maintains a public list of AI-enabled medical devices authorized for marketing, which signals that health AI has moved from experimental enthusiasm into a regulated medical technology environment [1]. A 2025 review of 1,016 FDA authorizations found that quantitative image analysis remains the dominant use case, while newer applications increasingly extend into data generation and other clinical data types [2].
This point is strategically important. The strongest health-AI story is not simply that generative AI can answer patient questions. The stronger story is that AI is becoming embedded in diagnostics, clinical workflow, care coordination, public health intelligence, and drug-development infrastructure.
The Latest Innovation Wave: Multimodal, Workflow, and Regulated AI
The next major innovation wave is multimodal AI: systems that can process different types of inputs such as text, image, audio, video, laboratory data, imaging data, and electronic health-record content. WHO’s 2025 guidance on large multimodal models emphasizes their potential use across healthcare, scientific research, public health, and drug development, while also stressing the need for governance, safety, and accountability [3].
In practical terms, multimodal AI can help turn fragmented medical information into a more coherent clinical picture. A clinician may need to understand the patient’s symptoms, radiology results, laboratory findings, medication history, risk factors, and previous notes. AI can support this synthesis, but the final responsibility must remain clinically governed and human-accountable.
Workflow AI is equally important. The European Commission identifies use cases such as patient scheduling, billing, electronic health-record management, earlier detection, and operational optimization as areas where AI can reduce administrative pressure and support better care delivery [4]. In many health systems, administrative friction is not a side issue; it is one of the main barriers to timely care.
AI and Accessibility: The Core Health-System Value
Accessibility in healthcare is often misunderstood as physical access to a hospital or clinic. In reality, access also includes affordability, appointment availability, language, health literacy, digital inclusion, specialist reach, continuity of care, and the ability to receive follow-up after discharge.
AI can improve access when it is designed around the patient journey rather than around isolated tools. AI-enabled triage can help patients reach the right level of care earlier. Remote monitoring can help clinicians detect deterioration in chronic disease before a hospital admission becomes necessary. Language technologies can reduce communication barriers for migrants, refugees, international patients, and older adults. Smart scheduling can reduce missed appointments and long waiting times.
WHO’s vision for AI in health emphasizes safety, equity, and the advancement of the Sustainable Development Goals, with the explicit objective that AI should enhance health without leaving people behind [8]. This is the right policy lens: AI should be evaluated by whether it reduces inequity, not by whether it looks technologically impressive.
Drug Development and Clinical Trials: AI Moves Upstream
AI is also moving upstream into the evidence-generation process. In December 2025, the FDA qualified AIM-NASH as its first AI drug-development tool for use in MASH clinical trials. The tool analyzes liver biopsy images and provides scores under the NASH Clinical Research Network scoring system, while human pathologists remain responsible for final interpretation [5].
This development matters because it shows AI’s value beyond bedside diagnosis. AI may help reduce variability in clinical-trial assessments, support more consistent image interpretation, and accelerate parts of therapeutic development. However, this should be framed carefully. AI can improve efficiency in selected trial processes, but it does not replace clinical validation, regulatory review, safety monitoring, or long-term outcome evidence.
Medical Value Travel: From Treatment Abroad to Intelligent Care Corridors
Medical value travel is more than traditional medical tourism. It refers to cross-border health journeys where the value proposition is not only price, but also quality, continuity, transparency, patient experience, technological capability, and measurable outcomes.
The sector is growing rapidly, although estimates vary by research firm. Grand View Research estimates the global medical tourism market at USD 34.0 billion in 2025 and projects USD 38.6 billion in 2026 and USD 126.2 billion by 2035; the same source reports Türkiye as holding a 13.5% revenue share in 2025 [6]. These figures should be treated as market estimates, but they clearly show that international care is becoming a strategic health-services domain.
AI can improve this field by creating a safer and more coherent international patient pathway. Before travel, AI can support preliminary triage, document translation, risk profiling, clinic matching, treatment-plan comparison, cost transparency, and remote second opinions. During travel, AI can support multilingual communication, hospital navigation, medication instructions, discharge education, and coordination between medical teams and facilitators. After travel, AI can support remote follow-up, rehabilitation tracking, complication alerts, patient satisfaction monitoring, and continuity between the destination provider and the home-country clinician.
Recent research on the digital patient journey in medical tourism highlights the importance of inclusivity, accessibility, continuity of care, and trust, especially for vulnerable patient groups [7]. A separate AI-focused medical tourism framework identifies stages such as information search, planning and reservation, travel and treatment, post-treatment follow-up, and feedback and loyalty [9]. These stages show exactly where AI can add operational and clinical value.
AI-Enabled Patient Journey: Access and Medical Value Travel
| Patient-journey stage | AI-enabled capability | Value for access and medical travel |
| Before care | Triage, risk profiling, document translation, appointment routing, remote second opinion | Reduces confusion, waiting time, travel uncertainty, and language barriers |
| During care | Clinical decision support, imaging support, workflow automation, multilingual navigation | Improves coordination, patient understanding, and service quality |
| After care | Remote monitoring, rehabilitation tracking, medication reminders, complication alerts | Strengthens continuity and reduces avoidable readmissions or unsafe follow-up gaps |
| System level | Demand forecasting, scheduling optimization, resource allocation, outcome monitoring | Supports scalable service delivery and more accountable international patient programs |
The Governance Challenge: Trust Is Now a Competitive Advantage
The major risk is that AI could widen inequity instead of reducing it. If AI tools are trained on incomplete, biased, or non-representative data, they may perform less accurately for some populations. If digital tools are deployed without attention to language, literacy, disability, or internet access, they can exclude the very groups that most need better access.
For medical value travel, the trust issue is even sharper. International patients face unfamiliar legal systems, language barriers, uneven information, and uncertainty about follow-up. AI should not be used merely as a marketing engine. It should be used as a trust infrastructure: verified provider information, clear consent, transparent pricing, documented outcomes, safe data-sharing, and accountable post-treatment follow-up.
The most advanced providers will not be those that simply advertise AI. They will be those that can prove clinical governance, data protection, transparent workflows, and measurable patient outcomes. In this emerging market, trust will be a strategic asset.
Strategic Takeaway
The future of AI in health is not only digital; it is institutional. AI will deliver real value when it is integrated into care pathways, workforce design, patient communication, international care coordination, and outcome measurement.
For accessibility, AI’s promise is to bring health services closer to people. For medical value travel, its promise is to make cross-border care safer, more transparent, and more continuous. For healthcare as a whole, the goal should not be to replace the human dimension of medicine. The goal should be to protect it by reducing administrative load, supporting earlier diagnosis, improving continuity, and helping patients move through the system with less confusion and more confidence.
Bottom line: AI should be assessed by the quality of access it creates, the safety of the pathway it supports, and the continuity of care it enables—not by the novelty of the technology alone.
References
[1] U.S. Food and Drug Administration. Artificial Intelligence-Enabled Medical Devices. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices
[2] Singh, R., et al. (2025). How AI is used in FDA-authorized medical devices. npj Digital Medicine. https://www.nature.com/articles/s41746-025-01800-1
[3] World Health Organization. (2025). Ethics and governance of artificial intelligence for health: Guidance on large multi-modal models. https://www.who.int/publications/i/item/9789240084759
[4] European Commission. Artificial Intelligence in healthcare. https://health.ec.europa.eu/ehealth-digital-health-and-care/artificial-intelligence-healthcare_en
[5] U.S. Food and Drug Administration. (2025). FDA qualifies first AI drug development tool; will be used in MASH clinical trials. https://www.fda.gov/drugs/drug-safety-and-availability/fda-qualifies-first-ai-drug-development-tool-will-be-used-mash-clinical-trials
[6] Grand View Research. Medical Tourism Market Size & Share Report, 2026-2035. https://www.grandviewresearch.com/industry-analysis/medical-tourism-market
[7] Bovsh, L. (2026). Digital patient journey in medical tourism: experiences from Ukraine under conditions of military challenges and global crises. Exploration of Digital Health Technologies. https://www.explorationpub.com/Journals/edht/Article/101189
[8] World Health Organization. Harnessing artificial intelligence for health. https://www.who.int/teams/digital-health-and-innovation/harnessing-artificial-intelligence-for-health
[9] Karcıoğlu, U. B. The impact of artificial intelligence on the patient journey in medical tourism: A management framework. https://dergipark.org.tr/en/pub/ehta/article/1701664